Philip Morris (PM) Q4 2025 earnings review
Smoke-Free Transition Pays Off, But 2026 Hurdles Loom
Philip Morris International capped an outstanding 2025 with $40.6B in revenue (+7.3%) and a 14.2% jump in adjusted currency-neutral EPS. The structural pivot is undeniable: Smoke-Free Products (SFP) now generate nearly 43% of total gross profit, with margins surpassing combustibles. However, Q4 revealed friction—U.S. ZYN growth optically slowed due to inventory destocking, and guidance for 2026 indicates deceleration (EPS growth +7.5-9.5%) driven by Japanese excise taxes and tougher comps.
🐂 Bull Case
The thesis is working: Smoke-Free gross margins hit 69.5% in FY25, now 400 basis points higher than combustibles. As SFP mix grows (now 41.5% of revenue), it structurally lifts the company's profitability profile.
Despite Q4 inventory noise, U.S. ZYN shipments grew 37% in FY25 to 794M cans. Management estimates underlying consumer offtake grew 25%, and the brand commands ~40% global category share with premium pricing power.
🐻 Bear Case
After a stellar +14.2% EPS growth in 2025, guidance calls for +7.5-9.5% in 2026. This deceleration is driven by specific headwinds: Japanese excise tax hikes and significant excise increases in India and Mexico.
Q4 ZYN shipments (196M cans) trailed Q3 (206M), reflecting 5M cans of destocking. While management cites 'surplus inventory' normalization in Q1 2026, the gap between shipments and offtake creates short-term forecasting risk.
⚖️ Verdict: 🟢
Constructive. PMI is proving that its 'smoke-free future' is highly profitable, not just a slogan. While 2026 faces understandable tax and comp headwinds, the underlying engine—pricing power in cigarettes funding high-margin SFP growth—remains intact.
Key Themes
Margin Expansion Story is Real
The most critical data point for long-term investors is the profitability crossover. Smoke-free products are no longer dilutive or just 'promising'; they are accretive. Adjusted Gross Margin for SFP expanded 270bps to 69.5% in FY25, while Combustibles stood at 65.5%. This mix shift drove total organic Operating Income up 10.6%.
Japan Excise Tax Headwind
Japan, the bellwether for heated tobacco, poses a risk for 2026. Excise taxes on heat-not-burn (HNB) products will rise in April and October. Management expects this to impact volume and category growth due to price elasticity. PMI has applied for price increases, but 2026 is labeled an 'atypical year' with potential shipment volatility.
ZYN International & VEEV Acceleration
The smoke-free story is broadening beyond just IQOS and U.S. ZYN. International ZYN shipments (ex-Nordics) grew >100% in Q4. VEEV (e-vapor) shipments doubled in FY25, reaching #1 closed-pod share in 8 markets. This diversification reduces reliance on single markets.
U.S. ZYN: Destocking & Competition
Q4 U.S. ZYN shipments grew 19% YoY, a deceleration from the +37% full-year pace. The discrepancy between shipments (794M cans) and offtake (~740-750M cans) implies a channel inventory build earlier in the year that began unwinding in Q4. Management flagged ~25M cans of surplus inventory still in the chain, expected to clear in Q1 2026.
Combustible Pricing Power Persists
Despite a volume decline of 1.5% in FY25, Combustible Net Revenue grew +2.5% reported and +1.8% organic. This was fueled by strong pricing (+7.6% variance for full year). This pricing power effectively offsets volume erosion and funds the transition, though management warns of tougher comps in 2026.
Currency Volatility
Currency remains a drag. While reported EPS grew strongly, currency headwinds cost $0.28 per share in FY25. For 2026, guidance assumes a $0.27 benefit, but Q4 saw non-recurring transactional losses related to the Russian Ruble and Swiss Franc, signaling continued FX sensitivity.
Other KPIs
Accelerating. Up from +10.5% for the full year. This metric (In-Market Sales) strips out inventory noise and shows strong underlying demand for heated tobacco, particularly in Europe and Japan (adjusted share +2.0pp to 32.6%).
Stable. Matches the record delivery of 2024. This strong cash generation enabled a dividend payout ratio near the 75% target and supports the deleveraging goal of ~2.0x Net Debt/EBITDA by end of 2026.
Stable/Resilient. Smoke-free products now comprise >50% of net revenue in this region. Despite flavor bans in the EU, IQOS IMS accelerated to 10.3% in Q4, proving portfolio resilience.
Guidance
Decelerating. The implied growth rate of 7.5% - 9.5% is a step down from the 14.2% achieved in 2025. Management cites a 'high base,' Japanese excise taxes, and a 3% projected decline in cigarette volumes (vs 1.5% in '25) as reasons.
Stable. Broadly consistent with the 6.5% achieved in FY25. Assumes continued smoke-free volume growth (high single-digits) offsetting cigarette declines.
Stable/Monitoring. Management did not provide a specific can count guidance range in the summary, unlike prior quarters, but noted growth will track offtake after inventory normalization in Q1.
Accelerating. Up from $12.2B in 2025. This cash generation is critical for the target of deleveraging to ~2.0x Net Debt/EBITDA by year-end 2026.
Key Questions
ZYN U.S. Elasticity
With a price increase of $0.10/can announced in Dec '25 and elevated promotional intensity in the category, how is consumer retention trending in Q1 '26 versus lower-priced competitors?
Japan Excise Quantified
Can you quantify the gross margin impact of the Japanese excise tax changes in 2026? How much of the tax hike is being passed through to consumers versus absorbed?
IQOS U.S. Launch Timing
The ILUMA application is still pending with the FDA. Does the 2026 guidance assume any meaningful contribution from a U.S. IQOS launch, or is this entirely pushed to 2027+?